Objectives. Treatment with pamidronate improves the clinical course in children with
osteogenesis imperfecta (OI), but theoretically might affect longitudinal growth. In this study …

Clinical and histomorphometric outcome was compared between children with OI who had
received pamidronate since infancy and age‐matched patients who had never received …

Context: Intravenous pamidronate treatment is beneficial to children and adolescents with
osteogenesis imperfecta (OI), but the effects of prolonged therapy are not well characterized …

Severe osteogenesis imperfecta (OI) is a hereditary disorder characterized by increased
bone fragility and progressive bone deformity. Cyclical pamidronate infusions improve …

Context: Cyclical iv pamidronate is a widely used symptomatic therapy of osteogenesis
imperfecta (OI). What happens after treatment discontinuation is unknown. Objective: The …

Objective: Evaluate clinical outcome of early cyclic intravenous pamidronate treatment in
children with moderate-to-severe osteogenesis imperfecta (OI), commenced before three …

Cyclical intravenous therapy with pamidronate improves the clinical course in children and
adolescents with osteogenesis imperfecta (OI). In this study, we evaluated the effect of this …

Intravenous treatment with pamidronate is beneficial in children and adolescents with
moderate to severe forms of osteogenesis imperfecta (OI) types I, III and IV, but there is little …

A prospective open study was performed to determine the efficacy and safety of pamidronate
in improving bone mineralisation and reducing fracture incidence in osteogenesis …

Objectives.–To study the efficacy of pamidronate in children with osteogenesis imperfecta
(OI). Patients and methods.–Twenty-nine patients (median age 8.7 years), were given …